Wilkowski, R. and Boeck, S. and Ostermaier, S. and Sauer, R. and Herbst, M. and Fietkau, R. and Flentje, M. and Miethe, S. and Boettcher, H. D. and Scholten, T. and Bruns, C. J. and Rau, H. G. and Hinke, A. and Heinemann, V. (2009) Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer - a multi-centre randomised phase II study. BRITISH JOURNAL OF CANCER, 101 (11). pp. 1853-1859. ISSN 0007-0920, 1532-1827
Full text not available from this repository. (Request a copy)Abstract
BACKGROUND: No standard treatment for locally advanced pancreatic cancer (LAPC) is defined. PATIENTS AND METHODS: Within a multi-centre, randomised phase II trial, 95 patients with LAPC were assigned to three different chemoradiotherapy (CRT) regimens: patients received conventionally fractionated radiotherapy of 50 Gy and were randomised to concurrent 5-fluorouracil (350 mg m(-2) per day on each day of radiotherapy, RT-5-FU arm), concurrent gemcitabine (300 mg m(-2)), and cisplatin (30 mg m(-2)) on days 1, 8, 22, and 29 (RT-GC arm), or the same concurrent treatment followed by sequential full-dose gemcitabine (1000 mg m(-2)) and cisplatin (50 mg m(-2)) every 2 weeks (RT-GC + GC arm). Primary end point was the overall survival (OS) rate after 9 months. RESULTS: The 9-month OS rate was 58% in the RT-5-FU arm, 52% in the RT-GC arm, and 45% in the RT-GC + GC arm. Corresponding median survival times were 9.6, 9.3, and 7.3 months (P = 0.61) respectively. The intent-to-treat response rate was 19, 22, and 13% respectively. Median progression-free survival was estimated with 4.0, 5.6, and 6.0 months (P = 0.21). Grade 3/4 haematological toxicities were more frequent in the two GC-containing arms, no grade 3/4 febrile neutropaenia was observed. CONCLUSION: None of the three CRT regimens tested met the investigators' definition for efficacy; the median OS was similar to those previously reported with gemcitabine alone in LAPC. British Journal of Cancer (2009) 101, 1853-1859. doi:10.1038/sj.bjc.6605420 www.bjcancer.com Published online 10 November 2009 (C) 2009 Cancer Research UK
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | FULL-DOSE GEMCITABINE; CONSOLIDATIVE CHEMORADIATION; RADIATION-THERAPY; PLUS GEMCITABINE; TRIAL; RADIOTHERAPY; ADENOCARCINOMA; CAPECITABINE; OXALIPLATIN; COMBINATION; chemoradiotherapy; cisplatin; gemcitabine; pancreatic cancer |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Strahlentherapie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 01 Sep 2020 11:16 |
| Last Modified: | 01 Sep 2020 11:16 |
| URI: | https://pred.uni-regensburg.de/id/eprint/28110 |
Actions (login required)
 |
View Item |
